Panobinostat is under clinical development by Secura Bio and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 14% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Panobinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Panobinostat (Farydak) is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. It is formulated as hard gelatin capsules for the oral route of administration. Panobinostat is indicated in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.
Panobinostat (LBH589) is under development for the treatment of pediatric patients with diffuse intrinsic pontine glioma (DIPG), graft versus host disease (GVHD), sickle cell disease, HIV-1 infections. The drug candidate was also under development for the treatment of Huntington's disease, hematological tumors such as thyroid cancer, multiple myeloma, acute myelocytic leukemia, myelodysplastic syndrome, diffuse large B-cell lymphoma, thrombocythaemia myelofibrosis, myelofibrosis, refractory cutaneous T-cell lymphoma, post-polycythemia vera myelofibrosis (PPV-MF), acute lymphocytic leukemia, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, recurrent high grade glioma, chronic lymphocytic leukemia (CLL), esophageal cancer, gastric cancer, colorectal cancer, head and neck cancer, Hodgkin lymphoma, small-cell lung cancer, adult T-cell lymphoma, mantle cell lymphoma, thyroid cancer, adult T-cell leukemia, chronic myelocytic leukemia, osteosarcoma, malignant rhabdoid tumor, atypical teratoid rhabdoid tumor (MRT/ATRT), and neuroblastoma, non-small cell lung cancer, hepatocellular carcinoma, metastatic melanoma, HER -2 positive metastatic breast cancer, neuroendocrine tumors, metastatic renal cell carcinoma, refractory chronic myelocytic leukemia and recurrent malignant gliomas.
Secura Bio overview
Secura Bio is a pharmaceutical company that develops innovative therapies and drugs. Its product portfolio includes COPIKTRA medicine, which is used for treating patients with Chronic Lymphocytic Leukemia (CLL) and COPIKTRA (duvelisib) a kinase inhibitor which is used to treat the patients with Relapsed or refractory CLL or SLL. The company has its operations in the US and Ireland. Secura Bio is headquartered in Las Vegas, Nevada, the US.
For a complete picture of Panobinostat’s drug-specific PTSR and LoA scores, buy the report here.